Abstract
Decitabine (Dacogen; MGI Pharma), a nucleoside analogue that inhibits DNA methylation, was approved by the US FDA for the treatment of myelodysplastic syndromes in May 2006.
Original language | English (US) |
---|---|
Pages (from-to) | 891-892 |
Number of pages | 2 |
Journal | Nature Reviews Drug Discovery |
Volume | 5 |
Issue number | 11 |
DOIs | |
State | Published - Nov 2006 |
Externally published | Yes |
ASJC Scopus subject areas
- Pharmacology
- Drug Discovery